TaiMed Biologics
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinica… Read more
TaiMed Biologics (4147) - Net Assets
Latest net assets as of September 2025: NT$3.92 Billion TWD
Based on the latest financial reports, TaiMed Biologics (4147) has net assets worth NT$3.92 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$4.82 Billion) and total liabilities (NT$896.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$3.92 Billion |
| % of Total Assets | 81.39% |
| Annual Growth Rate | 13.55% |
| 5-Year Change | 17.77% |
| 10-Year Change | -17.9% |
| Growth Volatility | 63.64 |
TaiMed Biologics - Net Assets Trend (2009–2024)
This chart illustrates how TaiMed Biologics's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for TaiMed Biologics (2009–2024)
The table below shows the annual net assets of TaiMed Biologics from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$4.02 Billion | +56.77% |
| 2023-12-31 | NT$2.57 Billion | -5.48% |
| 2022-12-31 | NT$2.71 Billion | -7.70% |
| 2021-12-31 | NT$2.94 Billion | -13.89% |
| 2020-12-31 | NT$3.42 Billion | -4.75% |
| 2019-12-31 | NT$3.59 Billion | -12.11% |
| 2018-12-31 | NT$4.08 Billion | -4.93% |
| 2017-12-31 | NT$4.29 Billion | -8.94% |
| 2016-12-31 | NT$4.71 Billion | -3.80% |
| 2015-12-31 | NT$4.90 Billion | +167.70% |
| 2014-12-31 | NT$1.83 Billion | +178.28% |
| 2013-12-31 | NT$657.73 Million | +1.94% |
| 2012-12-31 | NT$645.21 Million | -23.12% |
| 2011-12-31 | NT$839.24 Million | -19.39% |
| 2010-12-31 | NT$1.04 Billion | +74.06% |
| 2009-12-31 | NT$598.14 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to TaiMed Biologics's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 113638700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$5.16 Billion | 128.25% |
| Total Equity | NT$4.02 Billion | 100.00% |
TaiMed Biologics Competitors by Market Cap
The table below lists competitors of TaiMed Biologics ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PT. Indika Energy Tbk
F:I41
|
$290.15 Million |
|
Red 5 Limited
PINK:REDLF
|
$290.26 Million |
|
SintokogioLtd
PINK:SILDF
|
$290.29 Million |
|
BLUELINX HLDGS DL-01
F:FZG1
|
$290.34 Million |
|
Altri SGPS SA
LS:ALTR
|
$289.91 Million |
|
SELECT HARVEST
F:H0I
|
$289.83 Million |
|
Shenzhen King Explorer Science and Technology Corp Class A
SHE:002917
|
$289.77 Million |
|
Zhejiang Zuch Technology Co. Ltd. A
SHE:301280
|
$289.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TaiMed Biologics's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,566,086,000 to 4,022,909,000, a change of 1,456,823,000 (56.8%).
- Net loss of 201,832,000 reduced equity.
- New share issuances of 1,645,325,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-201.83 Million | -5.02% |
| Share Issuances | NT$1.65 Billion | +40.9% |
| Other Changes | NT$13.33 Million | +0.33% |
| Total Change | NT$- | 56.77% |
Book Value vs Market Value Analysis
This analysis compares TaiMed Biologics's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.52x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.02x to 3.52x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$17.15 | NT$51.80 | x |
| 2018-12-31 | NT$16.23 | NT$51.80 | x |
| 2019-12-31 | NT$14.22 | NT$51.80 | x |
| 2020-12-31 | NT$13.54 | NT$51.80 | x |
| 2021-12-31 | NT$11.66 | NT$51.80 | x |
| 2022-12-31 | NT$10.75 | NT$51.80 | x |
| 2023-12-31 | NT$10.00 | NT$51.80 | x |
| 2024-12-31 | NT$14.73 | NT$51.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TaiMed Biologics utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.02%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -33.08%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 1.24x
- Recent ROE (-5.02%) is above the historical average (-9.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -9.63% | 0.00% | 0.00x | 1.01x | NT$-961.66 Million |
| 2016 | -5.98% | -13581.98% | 0.00x | 1.02x | NT$-753.34 Million |
| 2017 | -12.22% | -6218.04% | 0.00x | 1.05x | NT$-953.78 Million |
| 2018 | -7.88% | -133.47% | 0.05x | 1.17x | NT$-729.76 Million |
| 2019 | -16.13% | -82.14% | 0.15x | 1.32x | NT$-937.29 Million |
| 2020 | -5.37% | -25.37% | 0.14x | 1.52x | NT$-524.89 Million |
| 2021 | -16.01% | -113.91% | 0.09x | 1.57x | NT$-765.08 Million |
| 2022 | -9.92% | -47.83% | 0.14x | 1.51x | NT$-540.78 Million |
| 2023 | -7.59% | -39.61% | 0.13x | 1.52x | NT$-451.42 Million |
| 2024 | -5.02% | -33.08% | 0.12x | 1.24x | NT$-604.12 Million |
Industry Comparison
This section compares TaiMed Biologics's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,107,525,400
- Average return on equity (ROE) among peers: 2.82%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TaiMed Biologics (4147) | NT$3.92 Billion | -9.63% | 0.23x | $289.92 Million |
| Synbio Tech Inc. (1295) | $942.97 Million | 12.01% | 1.00x | $21.72K |
| Apex Biotechnology Corp (1733) | $842.42 Million | 19.18% | 0.14x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $875.36 Million | 7.09% | 0.89x | $129.07 Million |
| Panion & BF Biotech Inc (1760) | $278.86 Million | -14.55% | 2.31x | $123.88 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $2.02 Billion | 5.81% | 0.71x | $42.95 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.16 Billion | 13.75% | 0.60x | $45.13 Million |
| Level Biotechnology (3118) | $498.78 Million | 7.80% | 0.36x | $22.63 Million |
| GenMont Biotech Inc (3164) | $861.62 Million | 3.30% | 0.66x | $31.27 Million |
| Medigen Biotechnology (3176) | $3.18 Billion | -14.68% | 0.53x | $100.57 Million |
| Sagittarius Life Science (3205) | $419.76 Million | -11.56% | 0.24x | $56.40 Million |